The Angelman Syndrome Foundation (ASF) is a non-profit 501(c)(3) organization dedicated to advancing the understanding and treatment of Angelman syndrome, a rare neurodevelopmental disorder caused by loss of function of the UBE3A gene on chromosome 15. Founded in 1984, ASF serves as the primary patient advocacy organization for the Angelman community in the United States, funding research and supporting families affected by this condition.
To advance the understanding and treatment of Angelman syndrome through research, advocacy, and family support. The foundation's strategic priorities include: funding innovative research, facilitating clinical trials, providing family resources, and advocating for regulatory policies that accelerate therapy development.
ASF is a major non-governmental funder of Angelman syndrome research:
- Research grants: Annual grant cycles supporting basic science, translational, and clinical research on Angelman syndrome
- ASF Natural History Study: Multi-site natural history registry that has become a critical resource for clinical trial design, endpoint validation, and regulatory submissions
- Biomarker consortium: Support for development of quantitative biomarkers and outcome measures for clinical trials
- Therapeutic pipeline funding: Direct support for companies developing gene therapies, ASOs, and other interventions for Angelman
A defining partnership for ASF has been its collaboration with GeneTx Biotherapeutics, which led to the development of GTX-102:
- ASF identified UBE3A-ATS silencing as a promising therapeutic approach for Angelman syndrome
- The foundation provided early research funding that enabled GeneTx to advance GTX-102 from concept to clinical trials
- ASF has actively supported patient recruitment for the KIK-AS-02 (GTX-102) clinical trial
- GTX-102 received FDA Breakthrough Therapy Designation and a BLA submission is expected in Q3-Q4 2026
The foundation facilitates clinical development through:
- Patient registry: A comprehensive registry of genetically confirmed Angelman patients enabling rapid trial recruitment
- Site support: Working with companies to identify and prepare clinical trial sites in the US and internationally
- Natural history data: The ASF natural history study provides natural history data that can serve as external controls for single-arm trials, reducing placebo arm size
- Educational webinars: Regular updates for families on clinical trial design, eligibility, and outcomes
- Family resources: Educational materials, care guides, and information about available therapies and clinical trials
- Family conference: Annual conference bringing together families, researchers, and industry to share knowledge and build community
- Financial assistance: Emergency funds and equipment assistance for families facing financial hardship
- Early intervention support: Guidance on accessing early intervention services, educational support, and therapeutic interventions
ASF engages actively with regulatory agencies:
- FDA engagement: Participation in FDA Patient-Focused Drug Development meetings and external input processes
- Orphan drug designation: Supporting companies in obtaining orphan drug designation and rare pediatric disease priority review vouchers
- Accelerated approval pathway: Advocacy for accelerated approval based on biomarker or intermediate clinical endpoints
- International engagement: Collaboration with regulatory agencies in Europe and other regions
ASF has identified key therapeutic targets and research priorities:
- UBE3A replacement: AAV gene therapy approaches delivering functional UBE3A to neurons
- UBE3A-ATS silencing: ASO approaches to silence the antisense transcript and reactivate the paternal UBE3A allele (mechanism of GTX-102)
- Genetic editing: Base editing and prime editing approaches for precise UBE3A correction
- Symptomatic treatments: Novel anti-seizure medications, sleep interventions, and behavioral therapies
¶ Competitive Landscape
The Angelman therapy field is advancing rapidly, with ASF playing a central coordinating role:
| Program |
Company |
Modality |
Phase |
| GTX-102 |
GeneTx/Ultragenyx |
ASO (UBE3A-ATS silencing) |
Phase 2 (BLA expected Q3-Q4 2026) |
| AAV-UBE3A |
Multiple academic groups |
Gene therapy |
Preclinical |
| UBE3A base editing |
Various |
Genetic editing |
Preclinical |